EP3980016A4 - Compositions et méthodes de détection et de traitement de la thrombose et de plaques vasculaires - Google Patents

Compositions et méthodes de détection et de traitement de la thrombose et de plaques vasculaires Download PDF

Info

Publication number
EP3980016A4
EP3980016A4 EP20818536.3A EP20818536A EP3980016A4 EP 3980016 A4 EP3980016 A4 EP 3980016A4 EP 20818536 A EP20818536 A EP 20818536A EP 3980016 A4 EP3980016 A4 EP 3980016A4
Authority
EP
European Patent Office
Prior art keywords
compositions
detecting
methods
treating thrombosis
vascular plaques
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20818536.3A
Other languages
German (de)
English (en)
Other versions
EP3980016A1 (fr
Inventor
Evan C. Unger
Emmanuelle J. Meuillet
Iman DAYEI
Maria F. ACOSTA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microvascular Therapeutics LLC
Original Assignee
Microvascular Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microvascular Therapeutics LLC filed Critical Microvascular Therapeutics LLC
Publication of EP3980016A1 publication Critical patent/EP3980016A1/fr
Publication of EP3980016A4 publication Critical patent/EP3980016A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acoustics & Sound (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20818536.3A 2019-06-05 2020-06-01 Compositions et méthodes de détection et de traitement de la thrombose et de plaques vasculaires Pending EP3980016A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962857766P 2019-06-05 2019-06-05
PCT/US2020/035580 WO2020247315A1 (fr) 2019-06-05 2020-06-01 Compositions et méthodes de détection et de traitement de la thrombose et de plaques vasculaires

Publications (2)

Publication Number Publication Date
EP3980016A1 EP3980016A1 (fr) 2022-04-13
EP3980016A4 true EP3980016A4 (fr) 2023-11-15

Family

ID=73653328

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20818536.3A Pending EP3980016A4 (fr) 2019-06-05 2020-06-01 Compositions et méthodes de détection et de traitement de la thrombose et de plaques vasculaires

Country Status (8)

Country Link
US (2) US20220305143A1 (fr)
EP (1) EP3980016A4 (fr)
JP (1) JP2022535862A (fr)
KR (1) KR20220044244A (fr)
CN (1) CN114364383A (fr)
AU (1) AU2020288807A1 (fr)
CA (1) CA3142699A1 (fr)
WO (1) WO2020247315A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113848332B (zh) * 2021-09-17 2024-04-19 广州徕西姆医学诊断技术有限公司 一种血栓弹力图检测试剂及其制备方法和应用
WO2023107746A1 (fr) * 2021-12-10 2023-06-15 Microvascular Therapeutics, Llc Compositions et méthodes de détection et de traitement de la thrombose et de plaques vasculaires
KR20230171660A (ko) 2022-06-14 2023-12-21 오상민 공기 살균 정화기
WO2024050075A2 (fr) * 2022-09-01 2024-03-07 Microvascular Therapeutics, Llc Méthodes et compositions pour le traitement d'une obstruction vasculaire

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245318B1 (en) * 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
AU768859B2 (en) * 1999-07-29 2004-01-08 Dyax Corp. Binding moieties for fibrin
MXPA05007730A (es) * 2003-02-04 2006-01-31 Bracco Int Bv Agentes de contraste para ultrasonido y proceso para la preparacion de los mismos.
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
EP1866416A2 (fr) * 2005-03-22 2007-12-19 Medstar Health Inc. Systemes et methodes d'administration pour le diagnostic et le traitement de maladies cardio-vasculaires
JP5364589B2 (ja) * 2006-12-11 2013-12-11 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 診断および治療適用用フィブリン結合ペプチドコンジュゲート
EP2117603A2 (fr) * 2006-12-19 2009-11-18 Bracco International B.V. Composés de ciblage et composés thérapeutiques, et microvésicules remplies de gaz comprenant lesdits composés
CA2684752A1 (fr) * 2007-04-20 2008-10-30 Oregon Health & Science University Imagerie a ultrasons avec microbulles ciblees
JP2013507365A (ja) * 2009-10-07 2013-03-04 サンフォード−バーナム メディカル リサーチ インスティテュート 血餅結合脂質化合物に関する方法および組成物
US10279053B2 (en) * 2011-07-19 2019-05-07 Nuvox Pharma Llc Microbubble compositions, method of making same, and method using same
US20220023447A1 (en) * 2018-12-07 2022-01-27 Nanovalent Pharmaceuticals Inc. Fibrin-targeted polymerized shell lipid microbubbles for diagnostic and therapeutic applications

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DIMASTROMATTEO J ET AL: "In Vivo Molecular Imaging of Atherosclerotic Lesions in ApoE-/- Mice Using VCAM-1-Specific, 99mTc-Labeled Peptidic Sequences", THE JOURNAL OF NUCLEAR MEDICINE, vol. 54, no. 8, 29 May 2013 (2013-05-29), US, pages 1442 - 1449, XP055769109, ISSN: 0161-5505, DOI: 10.2967/jnumed.112.115675 *
FERNANDES S ET AL: "Adherence of platelet and fibrin targeted ultrasound contrast bubbles to human blood clots in vitro", ULTRASONICS SYMPOSIUM, 2008. IUS 2008. IEEE, IEEE, PISCATAWAY, NJ, USA, 2 November 2008 (2008-11-02), pages 349 - 352, XP031443665, ISBN: 978-1-4244-2428-3 *
GUO SHIFANG ET AL: "Reduced clot debris size in sonothrombolysis assisted with phase-change nanodroplets", ULTRASONICS SONOCHEMISTRY, vol. 54, 2 February 2019 (2019-02-02), pages 183 - 191, XP085662512, ISSN: 1350-4177, DOI: 10.1016/J.ULTSONCH.2019.02.001 *
KAUFMANN BA ET AL: "Molecular Imaging of Inflammation in Atherosclerosis With Targeted Ultrasound Detection of Vascular Cell Adhesion Molecule-1", CIRCULATION, vol. 116, no. 3, 17 July 2007 (2007-07-17), pages 276 - 284, XP055020746, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.106.684738 *
OLIVEIRA BL ET AL: "Peptide-based fibrin-targeting probes for thrombus imaging", DALTON TRANSACTIONS, vol. 46, no. 42, 1 January 2017 (2017-01-01), Cambridge, pages 14488 - 14508, XP055769108, ISSN: 1477-9226, DOI: 10.1039/C7DT02634J *
See also references of WO2020247315A1 *
UNGER E C ET AL: "In vitro studies of a new thrombus-specific ultrasound contrast agent", AMERICAN JOURNAL OF CARDIOLOGY, CAHNERS PUBLISHING CO., NEWTON, MA, US, vol. 81, no. 12A, 18 July 1998 (1998-07-18), pages 58G - 61G, XP002087505, ISSN: 0002-9149, DOI: 10.1016/S0002-9149(98)00055-1 *
WEINKAUF CC ET AL: "Endothelial vascular cell adhesion molecule 1 is a marker for high-risk carotid plaques and target for ultrasound molecular imaging", JOURNAL OF VASCULAR SURGERY, ELSEVIER, AMSTERDAM, NL, vol. 68, no. 6, 13 February 2018 (2018-02-13), XP085539932, ISSN: 0741-5214, DOI: 10.1016/J.JVS.2017.10.088 *

Also Published As

Publication number Publication date
AU2020288807A1 (en) 2022-01-20
WO2020247315A1 (fr) 2020-12-10
CN114364383A (zh) 2022-04-15
EP3980016A1 (fr) 2022-04-13
US20240148914A1 (en) 2024-05-09
KR20220044244A (ko) 2022-04-07
CA3142699A1 (fr) 2020-12-10
JP2022535862A (ja) 2022-08-10
US20220305143A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
EP3980016A4 (fr) Compositions et méthodes de détection et de traitement de la thrombose et de plaques vasculaires
IL290891A (en) Preparations and methods for the treatment of vascular diseases
PL3711730T3 (pl) Wyroby chłonne i sposoby wytwarzania
EP3833340A4 (fr) Compositions et procédés de traitement de la presbytie
EP4171606A4 (fr) Compositions et méthodes de traitement de la covid-19
IL308221A (en) Preparations and methods for treating depression
IL290892A (en) Methods for treating vascular diseases
IL288353A (en) Methods for treating cholangiocarcinoma
EP4003246A4 (fr) Compositions et procédés de traitement de la presbytie
IL312466A (en) PI3K-alpha inhibitors and methods for their preparation and use
IL289251A (en) Methods and preparations for the treatment of pancreatic cancer
IL299704A (en) Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using them
EP4110369A4 (fr) Méthodes de traitement et compositions associées
EP4017493A4 (fr) Méthodes de traitement utilisant bcn057 et bcn512
GB201913122D0 (en) Compositions and methods for treatment of cholangiocarcinoma
EP3937634A4 (fr) Matériaux et procédés pour le traitement et la prévention améliorés de biofilms
IL288415A (en) Combinations and methods for the treatment of hemochromatosis
IL287538A (en) Preparations and methods for the treatment of cancer
GB201913121D0 (en) Compositions and methods for treatment of cholangiocarcinoma
GB201913124D0 (en) Compositions and methods for treatment of cholangiocarcinoma
EP4034137A4 (fr) Compositions et procédés pour la prévention et le traitement de la pancréatite
EP4051308A4 (fr) Méthodes et compositions pour le traitement du syndrome de rett
EP4025258A4 (fr) Méthodes et compositions pour le traitement de la sclérose latérale amyotrophique
EP3917573A4 (fr) Procédés à base de crispr et nouvelles compositions pour le traitement de troubles vasculaires
EP3968994C0 (fr) Inhibiteurs abhd12 et leurs procédés de fabrication et d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230523

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/69 20170101ALI20230704BHEP

Ipc: A61K 47/62 20170101ALI20230704BHEP

Ipc: A61K 49/22 20060101ALI20230704BHEP

Ipc: A61K 41/00 20200101ALI20230704BHEP

Ipc: C12N 5/00 20060101ALI20230704BHEP

Ipc: A61K 31/496 20060101AFI20230704BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20231018

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/69 20170101ALI20231012BHEP

Ipc: A61K 47/62 20170101ALI20231012BHEP

Ipc: A61K 49/22 20060101ALI20231012BHEP

Ipc: A61K 41/00 20200101ALI20231012BHEP

Ipc: C12N 5/00 20060101ALI20231012BHEP

Ipc: A61K 31/496 20060101AFI20231012BHEP